OKYO Pharma (OKYO) Enterprise Value (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Enterprise Value of -$20.6 million for Q1 2026, down 1219.38% year-over-year from $1.8 million in Q1 2025, and down 387.97% quarter-over-quarter from -$4.2 million in Q3 2025.
OKYO Pharma (OKYO) Enterprise Value (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Enterprise Value for 6 consecutive years, with -$20.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 1219.38% year-over-year to -$20.6 million; the TTM figure through Mar 2026 stood at -$20.6 million (down 1219.38% YoY), while the FY2026 annual figure was -$20.6 million, down 1219.38% from the prior year.
- Enterprise Value retreated to -$20.6 million in Q1 2026 per OKYO's latest filing, from -$4.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$826848.0 in Q1 2024 and bottomed at -$20.6 million in Q1 2026.
- Historically, Enterprise Value has averaged -$4.6 million across 5 years, with a median of -$2.2 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 79.56% — and 2026, when it sank 1219.38%.
- OKYO Pharma's Enterprise Value stood at -$2.7 million in 2022, then jumped by 40.11% to -$1.6 million in 2023, then soared by 38.97% to -$987199.0 in 2024, then tumbled by 327.51% to -$4.2 million in 2025, then plunged by 387.97% to -$20.6 million in 2026.
- Business Quant data shows OKYO's Enterprise Value at -$20.6 million in Q1 2026, -$4.2 million in Q3 2025, and -$1.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | OKYO Pharma | 1.47 Bn | 1.47 Bn | - | -14.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.59 Mn |
| Sep 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Sep 30, 2024 | -987,199.00 |
| Mar 31, 2024 | -826,848.00 |
| Sep 30, 2023 | -1.62 Mn |
| Mar 31, 2023 | -4.05 Mn |
| Mar 31, 2022 | -2.70 Mn |
| Mar 31, 2021 | -6.89 Mn |